United States of America based
Erasca creating a new generation of oncology drugs intended to not just treat, but actually cure Cancer.
TechnologiesAI Companies (Drug Discovery)
Posts Mentioning This Company
This is a first-in-human, Phase 1/1b, open-label, multicenter clinical study of ERAS-601 SHP2 inhibitor as a monotherapy and in combination with a MEK inhibitor. The study will commence with dose escalation of ERAS-601 monotherapy, followed by dose escalation of ERAS-601 in combination with a MEK inhibitor. Once the monotherapy maximum tolerated dose (MTD) and/or recommended dose (RD) has been determined, then dose expansion of ERAS-601 monotherapy may commence. Dose expansion of ERAS-601 in combination with a MEK inhibitor may commence after the combination RD has been determined. Dose expansion will enroll participants with advanced or metastatic solid tumors harboring specific molecular alterations.
ERAS-007, a potential best-in-class inhibitor of the extracellular signal-regulated kinase (ERK), the most distal node of the RAS/MAPK pathway, was acquired from ASN Product Development, Inc., a wholly-owned subsidiary of Asana BioSciences, LLC.
“We are proud for Erasca to continue the development of ERAS-007 after Asana achieved a critical inflection point, demonstrating safety and durable efficacy, including multiple objective responses with complete and partial regression of target lesions, in a Phase 1 clinical study,” said Sandeep Gupta, Ph.D., Asana’s founder, president and CEO. “Erasca’s bold mission to erase cancer, its team’s prior experience in leading multiple global regulatory approvals, and their robust portfolio make Erasca the ideal partner to advance this program into later-stage development and commercialization.”
Erasca Announces Presentation of Preclinical Data on ERAS-801, a CNS-Penetrant EGFR Inhibitor with Broad Activity against Oncogenic EGFR Alterations, at AACR Conference on Brain Cancer
No services posted yet